Literature DB >> 20551521

Weiss criteria in large adrenocortical tumors: a validation study.

Manoj Jain1, Shalini Kapoor, Anand Mishra, Sushil Gupta, Amit Agarwal.   

Abstract

BACKGROUND: Several systems including pathologic criteria alone or in combination with clinical features have been proposed to differentiate between benign and malignant adrenocortical tumors and assess their prognosis. The Weiss system appears to be the most commonly used method for assessing malignancy but there are only a few studies which have evaluated its diagnostic power. Since we see large adrenocortical carcinoma (ACC), we attempt to evaluate the diagnostic power of Weiss system in large ACC.
MATERIALS AND METHODS: In this study clinicopathological characteristics of 42 adrenocortical neoplasms are studied and classified into adrenocortical adenoma (ACA) and ACC based on Weiss score of less than or equal to three or greater than three.
RESULTS: The histological criteria of Weiss appeared to predict tumor prognosis accurately. Five year survival of patients with Weiss scores of less than or equal to three was 100% compared to 0% of those with Weiss scores greater than three. The average weights of ACA and ACC were 13.0 plus/minus 8.4 grams and 621.1 plus/minus 335.2 grams respectively; average sizes of ACA and ACC were 2.8 plus/minus 1.0 cmsand 13.6 plus/minus 3.7 cms respectively.
CONCLUSION: Weiss score was found to be a good prognostic factor for tumors of the adrenal cortex.

Entities:  

Mesh:

Year:  2010        PMID: 20551521     DOI: 10.4103/0377-4929.64325

Source DB:  PubMed          Journal:  Indian J Pathol Microbiol        ISSN: 0377-4929            Impact factor:   0.740


  13 in total

1.  Genomic and immunohistochemical analysis in human adrenal cortical neoplasia reveal beta-catenin mutations as potential prognostic biomarker.

Authors:  Alexandra E Kovach; Carmelo Nucera; Quynh T Lam; Ahnthu Nguyen; Dora Dias-Santagata; Peter M Sadow
Journal:  Discoveries (Craiova)       Date:  2015 Apr-Jun

2.  Adrenocortical carcinoma surgery-surgical extent and approach.

Authors:  C Vanbrugghe; A J Lowery; C Golffier; D Taieb; F Sebag
Journal:  Langenbecks Arch Surg       Date:  2016-07-13       Impact factor: 3.445

3.  Virilizing adrenocortical carcinoma in a child: A rare enigma.

Authors:  Varuna Sipayya; Yogesh K Yadav; Rashmi Arora; Uma Sharma; Kusum Gupta
Journal:  Indian J Endocrinol Metab       Date:  2012-07

4.  Adrenocortical carcinoma: An extremely uncommon entity and the role of Immunohistochemistry in its diagnosis.

Authors:  G Gogoi; Manash P Baruah; P Borah; M Borgohain
Journal:  Indian J Endocrinol Metab       Date:  2012-12

5.  A rare case of synchronous adrenocortical carcinoma and renal cell carcinoma.

Authors:  Urmila Majhi; Kanchan M Murhekar; Mahendranath P Reddy; Kathiresan Narayanaswamy
Journal:  Indian J Endocrinol Metab       Date:  2011-07

6.  Adrenocortical carcinoma: Report of two cases.

Authors:  C Aparna; I V Renuka; G Saila Bala; P Annapurna
Journal:  Indian J Endocrinol Metab       Date:  2011-07

Review 7.  Feminizing adrenocortical tumors: Literature review.

Authors:  Farida Chentli; Ilyes Bekkaye; Said Azzoug
Journal:  Indian J Endocrinol Metab       Date:  2015 May-Jun

Review 8.  Pediatric genitourinary oncology.

Authors:  Francisco Tibor Dénes; Ricardo Jordão Duarte; Lílian Maria Cristófani; Roberto Iglesias Lopes
Journal:  Front Pediatr       Date:  2013-12-16       Impact factor: 3.418

9.  Histological scores and tumor size on stage II in adrenocortical carcinomas.

Authors:  Rui Caetano Oliveira; Maria João Martins; Carolina Moreno; Rui Almeida; João Carvalho; Paulo Teixeira; Miguel Teixeira; Edgar Tavares Silva; Isabel Paiva; Arnaldo Figueiredo; Maria Augusta Cipriano
Journal:  Rare Tumors       Date:  2021-06-27

10.  Cytodiagnosis of myxoid adrenocortical carcinoma and role of immunocytochemistry to differentiate it from renal cell carcinoma.

Authors:  Santosh Kumar Mondal; Senjuti Dasgupta; Palash Kumar Mandal; Mamata Guha Mallick Sinha
Journal:  J Cytol       Date:  2014-04       Impact factor: 1.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.